A therosclerotic peripheral arterial disease (PAD) is a major cause of morbidity in Western societies and significantly reduces quality of life in affected individuals. 1 The prevalence of PAD is dependent on the age of the population studied, the atherosclerotic risk factor profile, and the criteria used for diagnosis. In the United States, an estimated 20% of adults Ͼ70 years of age have PAD. Only one fifth of patients with objective evidence of PAD have the typical symptoms of intermittent limb claudication, whereas a significant percentage (30% to 50%) report atypical leg symptoms, and the remainder are asymptomatic. 2, 3 Although relatively few deaths are directly attributed to PAD, the disease is potently implicated in mortality. Both symptomatic PAD and asymptomatic PAD independently predict cardiovascular mortality. Moreover, occlusive PAD can progress to critical limb ischemia, a condition characterized by resting perfusion that is inadequate to maintain tissue viability. Patients with chronic critical limb ischemia have a 1-year mortality of 25% and a substantial rate of limb loss. 4 Although the goal of treatment in patients with limbthreatening ischemia is to preserve life and limb and to maintain function through the use of surgical or endovascular revascularization strategies, a significant number of patients have unreconstructable disease. Approximately 40% of these patients will require a major amputation within 6 months of the initial diagnosis. 2 Successful treatment of these patients requires new therapeutic approaches to reconstitute the microvasculature.
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Over the last 20 years, the explosion in our understanding of the regulation of angiogenesis resulted in identification of mediators capable of promoting new vessel formation in ischemic tissues. Experimental studies suggested that treatment with recombinant angiogenic growth factors such as vascular endothelial growth factor (VEGF) 5 and basic fibroblast growth factor (FGF) 6 stimulates collateral growth and augments revascularization in animal models of limb ische-mia. Because of the challenges in maintaining effective levels of recombinant growth factors in the ischemic area, strategies using angiogenic gene therapy were developed. 7 Controlled human trials administering a variety of angiogenic mediators, including VEGF, FGF-1, hepatocyte growth factor, and developmentally regulated locus-1, in patients with PAD indicated that these approaches are generally safe, but failed to produce consistent evidence of benefit. Moreover, concerns were raised about the quality of the vasculature generated on growth factor stimulation and about the possibility of proliferative effects on nonvascular cells. In the Regional Angiogenesis with VEGF (RAVE) trial, intramuscular adenoviral delivery of VEGF in patients with unilateral exerciselimiting claudication had no effects on primary efficacy end points but was associated with dose-dependent peripheral edema. 8 VEGF induces formation of hyperpermeable and proinflammatory vessels; the concerted actions of additional mediators (such as the angiopoietins and platelet-derived growth factor) may be required for their stabilization and maturation. On the other hand, members of the FGF family potently stimulate mitosis of several different cell types and may induce local fibrosis while triggering tumor growth. Thus, the search for safe and effective angiogenic strategies to reconstitute the vasculature of the ischemic limb continues.
In this issue of Circulation, Segers et al 9 identified stromal cell-derived factor (SDF)-1/CXCL12, a member of the CXC chemokine family with potent angiogenic properties, 10 as a promising therapeutic agent for the treatment of PAD. Experimental evidence has demonstrated that SDF-1 overexpression enhances angiogenesis in the ischemic mouse hind limb, promoting mobilization of endothelial progenitor cells. 11 However, the use of SDF-1 protein therapy to enhance angiogenesis was hampered by concerns regarding rapid inactivation of the chemokine in the protease-rich environment of the ischemic limb. SDF-1 processing by matrix metalloproteinase-2 results in generation of a neurotoxic fragment that does not bind to its main receptor, CXCR4, and lacks chemotactic activity for CD34ϩ hematopoietic progenitor cells. 12, 13 To ensure sustained SDF-1 activity in the hostile environment of the ischemic limb, Segers et al designed recombinant SDF-1 proteins carrying mutations that provide resistance to protease cleavage. One of these SDF-1 variants, SSDF-1(S4V), was resistant to processing by matrix metalloproteinase-2 and dipeptidyl peptidase IV but retained chemotactic activity in vitro and induced angiogenesis in vivo. Delivery of protease-resistant SDF-1 with the use of self-assembling nanofibers to achieve sustained local concentrations increased arteriolar density and enhanced blood flow in the ischemic mouse hind limb. Much like treatment with the angiogenic growth factors basic FGF and VEGF, administration of protease-resistant SDF-1 augments perfusion, increasing vascular density in the ischemic limb. Considering the established effects of VEGF and basic FGF administration in enhancing experimental ischemic angiogenesis, what additional role could SDF-1 treatment play? Is SDF-1 simply one more angiogenic mediator in our armamentarium? Compared with the effects of angiogenic growth factors, SDF-1 has unique properties. 14 As a chemokine, SDF-1 mediates angiogenesis by inducing chemotaxis of CXCR4ϩ progenitor cells. The absence of significant mitogenic actions on SDF-1 stimulation may prevent uncontrolled endothelial cell proliferation and subsequent formation of enlarged tortuous vessels, a common feature of VEGF-mediated angiogenesis, and may reduce the likelihood for tumor growth. In addition, generation of hyperpermeable vessels, a major characteristic of VEGF-stimulated neoangiogenesis, may not be observed after injection of SDF-1. However, the angiogenic pathways involving VEGF and SDF-1 are not independent. Extensive evidence suggests that SDF-1 upregulates VEGF synthesis in several different cell types, whereas VEGF and basic FGF induce SDF-1 and its receptor CXCR4 in endothelial cells. 10 In a transgenic system of VEGFmediated neovascularization, SDF-1 was a key mediator of retention of recruited bone marrow-derived cells in close proximity to angiogenic vessels. 15 These interactions provide a link between angiogenic growth factors and chemokineinduced angiogenesis.
Optimal exploitation of the SDF-1/CXCR4 axis in PAD requires better understanding of the mechanisms of action of the chemokine in the ischemic limb. Is SDF-1-mediated angiogenesis dependent solely on recruitment of CXCR4ϩ progenitors? Are the angiogenic effects of SDF-1 mediated, at least in part, through VEGF upregulation? The answers to these questions are key to understanding the interplay between various mediators of angiogenesis and to design therapeutic strategies combining protein and cell therapy approaches. Moreover, the effects of SDF-1 on the inflammatory response in the ischemic limb need to be understood. Evidence from in vivo studies in models of inflammatory injury is conflicting, suggesting that SDF-1 exerts context-dependent proinflammatory and antiinflammatory actions. 16 Finally, the role of SDF-1 in the generation of mature vessels remains unknown. A major limiting factor in angiogenic therapies is the formation of unstable vessels that may rapidly regress after cessation of treatment. 17 Whether SDF-1 mediates coating of the neovessels with pericytes and vascular maturation is not known. Formation of viable and stable neovessels in vivo may require the concerted effort of several distinct mediators.
By generating a protease-resistant variant, Segers and colleagues have introduced SDF-1 as a promising mediator for stimulation of angiogenesis in patients with PAD. The effectiveness of this approach in the clinical setting is impossible to predict on the basis of an experimental animal study. Beyond the possibility of species-specific actions, animal model investigations cannot simulate the complexity of the clinical environment. The goal of experimental studies is to test a hypothesis; for this reason, contextual factors are simplified to allow study of the effects of a specific intervention or genetic manipulation. Thus, the animals used for experimentation are typically young and healthy, and have the same genetic background. In contrast, patients with PAD are a highly heterogeneous group comprising older individuals with enormous genetic diversity and various comorbid conditions, such as diabetes mellitus, hypertension, and hyperlipidemia. Advanced age and diabetes mellitus are predictors of poor outcome in patients with PAD; their effects on SDF-1-mediated responses are unknown. Despite the challenges in translating this new strategy in the clinical context, stimulation of the SDF-1/CXCR4 axis represents an interesting and promising therapeutic approach to reconstitute the vasculature in PAD that may bridge classic angiogenic growth factor administration with cell therapy.
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